The introduction of 16s ribosomal RNA sequencing as a nonculture technique has led to the discovery of the presence of microbiota in the lower airways of healthy individuals. These bacterial communities may originate from the mouth and nasopharynx or from the environment by inhalation. The microbial composition of the lower airways may be modulated by dietary factors, antibiotic therapy, and microbial infections, particularly in early life. In addition, circulatory products from gut microbiota may influence the lung microbiota to maintain mucosal immunity. Recent studies have revealed that, in asthma, the lower airway microbiota show reduced diversity and community composition that is linked to severity and inflammatory phenotype. There is also a greater prevalence of proteobacteria, including Haemophilus, in symptomatic asthma. Microbial dysbiosis may contribute to both the inception and progression of asthma in infants and children, and to corticosteroid resistance in asthma. A better understanding of the regulation of the lung and gut microbiota in asthma may pave the way for targeting microbiota to prevent and treat asthma.
Clinicians have long recognized the link between asthma and bacterial infections. Although bacterial pathogens are often associated with exacerbations, they are also often present during the stable phase of airways disease, indicating chronic colonization. Bacterial species, such as Streptococcus pneumoniae, Staphyloccocus aureus, Moraxella catarrhalis, Pseudomonas aeruginosa, and Haemophilus influenzae have been cultured from sputum samples of patients with asthma during periods of exacerbations as well as during periods of clinical stability (1) (2) (3) . Acute wheezing episodes in preschool children of mothers with asthma have also been associated with these bacterial pathogens, with a frequency similar to that seen with viruses (4) . Atypical bacterial infections, such as Mycoplasma pneumonia and Chlamydia pneumonia, may also play a role in inducing and exacerbating asthma (5) .
The use of a culture-independent molecular microbiology profiling using high-throughput DNA sequencing of the highly conserved bacteria-specific gene, 16s ribosomal RNA (rRNA), has led to the discovery of a large range of bacterial communities in the gut consisting of 100 trillion micro-organisms and over 1,000 bacterial species that, acting as a community, stimulate the development of and modulate the innate and adaptive immune function at the mucosal surfaces of the gut and of other distant organs, such as the lungs. Microbial imbalance of the gut microbiota have also been implicated in the pathogenesis of diseases, such as inflammatory bowel disease, allergic diseases, including asthma, rheumatoid arthritis, depression, and obesity (6) .
Subsequent analysis of bronchial brushings and bronchial lavage fluid from healthy adult subjects by 16s rRNA sequencing has led to the identification of lower airway microbiota, indicating that the lower airways of the lungs are not sterile as previously thought (7, 8) . Microbiome mass decreases from the upper to lower respiratory tract by two to four orders of magnitude, and contains bacterial sequences similar to those obtained from upper respiratory flora (7). Alterations in the lung microbiota in asthma and chronic obstructive pulmonary disease (COPD) have also been reported, opening up the possibility that lung microbial imbalance or lung microbial dysbiosis could play a causative role in the pathogenesis of chronic airway diseases (8, 9) . The condition of asthma is now recognized to be heterogeneous in terms of its clinical presentation and severity, and also in terms of underlying mechanisms. This review summarizes the microbial dysbiotic findings in asthma and relates these abnormalities to certain phenotypes of asthma. Finally, the mechanistic evidence linking microbial dysbiosis to the development and pathophysiology of asthma will be presented.
Asthma Phenotypes
the airways with a diverse, heterogeneous presentation and a broad range of severity. More severe asthma is now established as a subset of disease that has been defined according to the European Respiratory Society and American Thoracic Society guidelines as asthma that requires treatment with high-dose inhaled corticosteroids plus a second controller and/or systemic corticosteroids to prevent it from becoming "uncontrolled" or that remains "uncontrolled" despite this therapy, once the diagnosis of asthma is confirmed and comorbidities addressed (10) . Severe asthma remains clearly a heterogeneous group with respect to its clinical and physiologic characteristics.
Although phenotypes of asthma have long been described by clinicians from their own experience of seeing patients with severe asthma, the recent use of statistical clustering approaches of cohorts with severe asthma has led to the identification of patients with little airflow obstruction and activity of disease, patients with early age of onset of disease with an atopic background, and a group of patients with more severe asthma associated with adult-onset active disease (11, 12) . In the asthma UBIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes) cohort, three clusters of severe asthma were reported: (1) late-onset severe asthma with a history of smoking and chronic airflow obstruction; (2) nonsmoking severe asthma with chronic airflow obstruction; and (3) obese female patients with frequent exacerbations, but with normal lung function (13) . Addition of eosinophilic inflammation in sputum samples in the clustering approach has led to the description of a cluster of an eosinophilic inflammationpredominant group with late-onset disease, and a high prevalence of rhinosinusitis, aspirin sensitivity, and exacerbations (12) . Clusters of noneosinophilic asthma may represent a diversity of phenotypes ranging from those with corticosteroid insensitivity and obesity to those with bacterial infections.
Using molecular phenotyping approach biased toward identifying T-helper cells type 2 (Th2)-high phenotypes, a Th2-high phenotype has been described in mildmoderate asthma with characteristics of eosinophilic inflammation, corticosteroid sensitivity, and expression of the Th2 cytokines, IL-5 and IL-13, in the airway wall (14) . The recent clinical trials of anti-IL-5 and anti-IL-4a receptor antibody treatments targeting patients with severe asthma showed significant clinical benefit in terms of exacerbations and FEV 1 in those with severe eosinophilic asthma, and support the existence of a Th2-high severe eosinophilic asthma (15) .
More recent unbiased approaches using molecular phenotyping of the transcriptome derived from bronchial epithelial cells and bronchial biopsies and sputum cells from patients with moderate-to-severe asthma have defined non-Th2, as well as confirming the Th2 molecular phenotypes (16, 17) . In the sputum, two non-Th2 molecular phenotypes were described, one dominated by inflammasome activation with neutrophilic inflammation in sputum, and the other one by mitochondrial oxidative stress with paucigranulocytic inflammation in sputum (17) . The presence of an activated inflammasome with neutrophilic inflammation evokes the possibility of a microbial dysbiosis that would activate the inflammasome and other pathways evoked in this cluster. Clearly, further elucidation of molecular clusters or endotypes of severe asthma would link up with the potential role of microbial dysbiosis with the inflammatory and innate immune response seen in subgroups of severe asthma.
Microbial Dysbiosis in Asthma
Up to 10 studies have been reported investigating airway/lung microbiota in asthma, with studies gathering patients with asthma with varying degrees of severity, and with a variety of techniques in collecting the airway samples using lower-airway samples from bronchoscopic studies or use of induced sputum (8, (18) (19) (20) (21) (22) (23) (24) (25) (26) . These studies vary in numbers and type of subjects investigated, and inconsistent sampling methodology may also represent an issue in comparing across studies. Thus, it has been reported that microbial diversity is lower and the load is higher in samples collected from upper respiratory tract, such as induced sputum compared with obtaining lower-airway samples through a bronchoscope (27) . However, despite these caveats, these studies show that there is a greater prevalence of proteobacteria, including Haemophilus, in mild asthma (8, 19, 20, 24) and that proteobacteria were associated with worse asthma symptoms and Th17-related genes (21) . There was a more diverse association with other species in more severe symptomatic asthma, such as Firmicutes (Streptococcus) (24) and Actinobacter (21) . Firmicutes (24) and Tropheryma whipplei (23) have been associated with eosinophilic asthma, whereas H. influenzae (23) and M. catarrhalis (20) have been associated with neutrophilic asthma. In one study, the level of eosinophilic inflammation correlated with variations in the microbiome across 23 steroid-free patients with asthma, whereas neutrophilic inflammation did not (26) . Those with low levels of eosinophils had more Neisseiria, Bacteroides, and Rotha species. Clearly, further analysis of the microbiota in asthma needs to include a larger number of subjects to confidently determine whether the inflammatory response is associated with lung dysbiosis.
Severe asthma is accompanied by the presence of comorbidities, such as obesity, rhinosinusitis, or gastroesophageal reflux disease or being on oral corticosteroid treatment, that themselves may influence the composition of lung microbiota. Thus, in patients with rhinosinusitis, there is an altered microbiota in the upper airways with an increased abundance of members of the genus Corynebacterium (28), which might contribute directly to the dysbiosis of the lower airways through microaspiration. There is an increasing recognition of a distinct phenotype of obesity-associated asthma (13, 29) . Obesity-related changes in gut microbiota may contribute to weight gain as well as to causing obesity-related asthma (30) . The NLR family pyrin domain containing 3 inflammasome and the proinflammatory cytokines, IL-17A and IL-1b, have been implicated in a mouse model of obesity-associated bronchial hyperresponsiveness (31) .
Association studies in asthma have not allowed us to definitively link microbial dysbiosis to any particular phenotype of asthma, but the study of Goleva and colleagues (32) has examined a potential microbial cause of corticosteroid insensitivity. In this study, corticosteroidresistant patients showed an overexpression of Haemophilus parainfluenzae in an analysis of bronchoalveolar lavage fluid; culture of H. parainfluenzae with macrophages induced corticosteroid resistance in these cells. Potentially, Th17 cells may be induced by bacterial infections, and they have been implicated in corticosteroid insensitivity (33, 34) .
TRANSATLANTIC AIRWAY CONFERENCE
Identification of Haemophilus, Streptococcus, Moraxella, Staphylococcus, Alloicoccus, or Corynebacteria in nasopharyngeal aspirates during the first year of life has been linked to a higher risk of developing asthma (35) . Haemophilus, Streptococcus, and Moraxella hypopharyngeal colonization have also been associated with increased risk of asthma exacerbations (4) and development of asthma (36) . Further support for the concept of certain bacteria being protective of the development of asthma comes from the studies of children brought up on farms who have a lower incidence of asthma compared with those not brought up on farms. Indeed, these children are exposed to a wider range of bacteria, as recovered in their environment (37) , and the higher content of endotoxin in the farm environment may account for the protective effect of that environment (38) . In another study of the Amish and Hutterite communities, which are two U.S. agricultural communities with similar lifestyles and yet with disparate levels of asthma and allergic conditions, it was the difference in microbial composition and levels of endotoxin in the house dust samples between the two communities that explained why the Amish had four-to sixfold lower prevalence of asthma and allergic conditions than the Hutterites (39).
How Can Microbial Dysbiosis Interfere with the Asthma Process?
The microbial composition of the lungs is several orders of magnitude lower than that in the gut and is remarkably similar to that from the oral cavity. This observation has led to the hypothesis that the microbes in the lungs arrived from the oral cavity, perhaps through a process of microaspiration (40) , or that certain bacteria are inhaled directly into the airways to colonize the airways (41) . What determines the final composition of the microbiome is likely to be a balance between entry by microaspiration and inhalation and elimination through coughing and ciliary clearance, in addition to local factors, such as acidity, oxygen tension, and presence of certain nutrients that would favor particular species (41) . The reasons for the microbial dysbiosis found in asthma are unclear at present. The fact that lung dysbiosis has now been described in other lung and airway conditions, such as COPD (42), bronchiectasis (43) , and pulmonary fibrosis (44), indicates perhaps that changes in the inflammatory conditions of the airways and lungs may favor certain species in that particular condition. Given the wide variety of bacterial species that have been described as dysbiotic, particularly in severe asthma, the question remains whether certain bacterial species are associated with a particular phenotype of asthma. To understand this association, it is important to determine the effect of these particular dysbiotic microbiota on the airways; for example, the demonstration by Goleva and colleagues (45) that H. parainfluenzae could induce corticosteroid insensitivity in alveolar macrophages.
Although 16s rRNA has opened up the golden era of the microbiome, sequence information from 16s rRNA amplicons is limited, and often does not unambiguously identify the species present. Therefore, to understand how microbial dysbiosis can affect asthma pathophysiology, improved approaches are necessary to unravel the composition and functional effects of microbial dysbiosis. Development of shotgun metagenomics approaches will allow for sequencing of the entire genomic component of the human microbiome, which will allow for both the composition and functional capacity of the microbiome to be investigated (46) . In a recent functional metagenomic study of the airway microbiome of COPD, a correlation between COPD severity measured by FEV 1 with differences in the abundance of S. pneumoniae was obtained and the degree of severity related to a reduced capacity for bacterial sialic acid metabolism (47) . This approach could therefore directly relate clinical features to features of the microbiome. Bioinformatic techniques should also be available to relate the metagenome with the host transcriptome or genome.
Mechanisms by which Microbial Dysbiosis May Cause Asthma
The observation of microbial dysbiosis in the lungs raises the question of mechanisms by which this may lead to a susceptibility to developing asthma or to the worsening of asthma symptoms. There is evidence to implicate various environmental factors in the development of asthma and allergic sensitization. Studies that have been supportive of the hygiene hypothesis have shown the protective effect of being more exposed to microbes in childhood, and the loss of protective effect when this exposure is reduced. Thus, protective conditions in early life have included living on a farm with exposure to livestock (48) , growing up in a household with dogs (49), breast feeding (50), and drinking unpasteurized milk (51) . Alterations of microbiota of nasal samples from schoolage farm and nonfarm children have been associated with asthma, with the presence of asthma being associated with Moraxella in children not exposed to farming (52) . Similarly, a reduced exposure to Firmicutes and Bacteroidetes has been associated with atopy and wheeze in children (53) . There is also evidence that exposure to high levels of endotoxin may be the basis for the reduced sensitization and allergic asthma found in children living in rural farms (38, 39) .
Neonatal bacterial dysbiosis has been associated with the development of recurrent wheeze in childhood indicating that early colonization with these organisms could influence the development of asthma. The relative abundance of Lachnospira, Veillonella, Faecalibacterium, and Rothia was decreased in children at risk of asthma (54) ; when germ-free mice were inoculated with these bacteria, their adult progeny were protected against airway inflammation, indicating a protective role for these bacterial taxa (54) . Associations between neonatal hypopharyngeal colonization with H. influenzae, S. pneumoniae, and M. catarrhalis, with the subsequent increased risk of developing recurrent wheezing and childhood asthma, have been reported (36, 55) . In addition, the presence of Haemophilus, Streptococcus, and Moraxella have been associated with an increased risk of asthma exacerbations (4) and the development of asthma (36) . Recent evidence indicates that formation of the airway microbiota induces regulatory cells early in life, which, when dysregulated, can lead to sustained susceptibility to allergic airway inflammation in adulthood (56) .
Another important issue is an understanding of the emerging interactions between lung microbiota with gut microbiota (57) . There is evidence in mice that gut microbiota may have an TRANSATLANTIC AIRWAY CONFERENCE S328 inhibitory influence on the development of Th2 responses. Germ-free sensitized mice have a greater Th2 response in their airways when challenged with ovalbumin compared with mice raised in the normal environment (58) . This notion of gut microbiome inhibiting Th2 responses is supported by experiments where depletion of microbiota was associated with more severe bacterial pneumococcal pneumonia (59) , indicating that gut microbiota plays a protective role in host defense against pneumonia. On the other hand, administration of bacterial LPS to the lungs of mice can lead to rapid changes in gut microbiota (60) . Alterations in both lung and gut microbiota in mice can be induced by intranasal administration of bacteria, such as Escherichia coli, Actinetobacter iwoffii (a bacterium from cowsheds), or Lactobacillus johnsonii (present in the human vaginal tract), all of which protected against the effects of allergen challenge with a reduction in Th2 allergic airway responses in sensitized mouse models of asthma (61) (62) (63) .
This cross-talk of gut-lung could also be provided by the production of metabolites, such as short-chain fatty acids (SCFAs) from the gut microbiome into the blood circulation to distribute it to the lungs and other organs (64) . The role of circulating SCFAs has been documented in a study in which dietary fermentable fiber fed to mice led to an alteration of the ratio of Firmicutes to Bacteroidetes in both gut and lung microbiota, that, in turn, caused an increase in circulating SCFA propionate that was associated with protection against allergic lung inflammation through an increase in CD25 1 CD4 1 T-regulatory cells (65) . SCFAs could also potentially modulate bone marrow-derived antigen-presenting cell precursors (66) .
It remains to be determined whether the respiratory microbiome is stable or variable, for example, during an asthma exacerbation. It is well appreciated that influenza infection predisposes to the development of secondary bacterial pneumonia. Rhinovirus infection, a common cause of exacerbations of asthma, does not change lung microbiota of healthy individuals, but in patients with COPD leads to a sixfold increase in proteobacteria, particularly H. influenzae (67) . There is also increasing evidence that persistent infection (or colonization) of the lower respiratory tract with potential pathogenic bacteria, as observed in chronic asthma, facilitates subsequent viral infections by increasing viral entry receptors and modulating the inflammatory response (68) . The respiratory mycobiome is another part of the microbial community that may be important in maintaining and establishing a healthy respiratory ecosystem, but may also impact the development and severity of airways/lung disease, and therefore merits further study (69) .
Conclusions
Significant work remains to be done to improve our understanding of the lung microbiota and its influence on the development and severity of asthma. The effect of environmental factors, such as living in polluted areas and dietary changes, and medications such as corticosteroids, b-adrenergic agonists, and anticholinergics, on lung microbiota are not known. How antibiotics used for treating respiratory and other infections change lung microbiota, and whether they can restore the lung dysbiosis of asthma, remains unclear. Finally, the mechanisms by which microbial dysbiosis contributes to the various characteristic traits of severe asthma, such as chronic airflow obstruction, exacerbations, and corticosteroid insensitivity, require further investigation. Understanding these mechanisms may facilitate the development of novel treatments directed at manipulating the microbiota to control and suppress mechanisms of allergic sensitization and asthma. n Author disclosures are available with the text of this article at www.atsjournals.org.
